On the management of menopause syndrome patients
Research objective. Development of a program of follow-up for women with menopausal metabolic syndrome and cholestasis; determination of the effectiveness of the Femoston in combination with Ursofalk. Materials and methods. 71 women with climacteric syndrome, obesity and cholestasis were under obser...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Book |
| Published: |
IP Berlin A.V.,
2013-06-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Research objective. Development of a program of follow-up for women with menopausal metabolic syndrome and cholestasis; determination of the effectiveness of the Femoston in combination with Ursofalk. Materials and methods. 71 women with climacteric syndrome, obesity and cholestasis were under observation; a comprehensive clinical and laboratory examination was carried out, measurement of modified menopausal index before treatment and after 6 months. The results. Positive changes in neurocirculation symptoms and lipid profile were obtained, a statistically significant reduction in transaminases and modified menopausal index, the coagulation parameters remained virtually unchanged. Conclusion. The Femoston and Ursofalk positively influence the climacteric syndrome; normalize lipid profile, having positive influence on the hepatobiliary system. It is appropriate to prescribe this medicine to the patients with menopausal metabolic syndrome and cholestasis. |
|---|---|
| Item Description: | 2079-5696 2079-5831 |